Literature DB >> 24938627

Symptom severity is associated with cardiovascular outcome in patients with permanent atrial fibrillation in the RACE II study.

Rob A Vermond1, Harry J G M Crijns2, Jan G P Tijssen3, A Marco Alings4, Maarten P Van den Berg1, Hans L Hillege5, Dirk J Van Veldhuisen1, Isabelle C Van Gelder1, Michiel Rienstra6.   

Abstract

AIMS: Symptoms and symptom burden have a central place in diagnosis and management of atrial fibrillation (AF). The aim of the present study is to investigate whether severity of AF symptoms impacts prognosis in permanent AF. METHODS AND
RESULTS: We studied the relation between AF symptom severity [quantified with the Toronto AF Severity Scale (AFSS)] and cardiovascular outcome in patients included in the RACE II study. The primary endpoint was a composite of cardiovascular morbidity and mortality. Secondary outcome was cardiovascular hospitalizations. Of 614 permanent AF patients in RACE II, AFSS questionnaires were available in 558 patients (91%). Mean age was 68 ± 8 years. One hundred and seventy-four patients (31%) reported a low score (score 0-3; lowest tertile), 190 patients (34%) reported a moderate score (score 4-9; middle tertile), and 194 (35%) reported a high score (score 10-35; highest tertile). Patients with the most severe symptoms were more often women, had higher N-terminal prohormone of brain natriuretic peptide concentrations, and had more previous heart failure hospitalizations. Median follow-up was 3.0 (interquartile range 2.3-3.0) years. The primary endpoint occurred most frequently in the highest tertile of the AFSS [16 (9%), 19 (10%), 36 (19%), respectively, P = 0.01], being mainly driven by heart failure hospitalizations [4 (2%), 1 (1%), 16 (8%), respectively, P < 0.001]. After multivariable adjustment, higher AFSS scores were associated with the primary endpoint [hazard ratio 1.38 (1.15-1.66), P = 0.001], as well as with cardiovascular hospitalizations [hazard ratio 1.33 (1.14-1.54), P < 0.001].
CONCLUSION: In permanent AF, after multivariable adjustment, symptom severity is associated with cardiovascular outcome. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2014. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Atrial fibrillation; Prognosis; Rate control; Symptoms; Treatment

Mesh:

Substances:

Year:  2014        PMID: 24938627     DOI: 10.1093/europace/euu151

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  9 in total

Review 1.  Tackling Patient-Reported Outcomes in Atrial Fibrillation and Heart Failure: Identifying Disease-Specific Symptoms?

Authors:  Benjamin A Steinberg; Jonathan P Piccini
Journal:  Cardiol Clin       Date:  2019-05       Impact factor: 2.213

Review 2.  Atrial Fibrillation Symptoms and Sex, Race, and Psychological Distress: A Literature Review.

Authors:  Kelly T Gleason; Saman Nazarian; Cheryl R Dennison Himmelfarb
Journal:  J Cardiovasc Nurs       Date:  2018 Mar/Apr       Impact factor: 2.083

3.  Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The DECAAF II Randomized Clinical Trial.

Authors:  Nassir F Marrouche; Oussama Wazni; Christopher McGann; Tom Greene; J Michael Dean; Lilas Dagher; Eugene Kholmovski; Moussa Mansour; Francis Marchlinski; David Wilber; Gerhard Hindricks; Christian Mahnkopf; Darryl Wells; Pierre Jais; Prashanthan Sanders; Johannes Brachmann; Jeroen J Bax; Leonie Morrison-de Boer; Thomas Deneke; Hugh Calkins; Christian Sohns; Nazem Akoum
Journal:  JAMA       Date:  2022-06-21       Impact factor: 157.335

4.  Association of sex, age and education level with patient reported outcomes in atrial fibrillation.

Authors:  Kelly T Gleason; Cheryl R Dennison Himmelfarb; Daniel E Ford; Harold Lehmann; Laura Samuel; Hae Ra Han; Sandeep K Jain; Gerald V Naccarelli; Vikas Aggarwal; Saman Nazarian
Journal:  BMC Cardiovasc Disord       Date:  2019-04-05       Impact factor: 2.298

5.  Psychosocial and cognitive multimorbidity and health-related quality of life and symptom burden in older adults with atrial fibrillation: The systematic assessment of geriatric elements in atrial fibrillation (SAGE-AF) cohort study.

Authors:  Benita A Bamgbade; Saket R Sanghai; David D McManus; Darleen Lessard; Molly E Waring; Sarah Forrester; Isabelle Pierre-Louis; Jane S Saczynski
Journal:  Arch Gerontol Geriatr       Date:  2020-05-28       Impact factor: 3.250

6.  Clinical utility of rhythm control by electrical cardioversion to assess the association between self-reported symptoms and rhythm status in patients with persistent atrial fibrillation.

Authors:  Astrid N L Hermans; Nikki A H A Pluymaekers; Theo A R Lankveld; Manouk J W van Mourik; Stef Zeemering; Trang Dinh; Dennis W den Uijl; Justin G L M Luermans; Kevin Vernooy; Harry J G M Crijns; Ulrich Schotten; Dominik Linz
Journal:  Int J Cardiol Heart Vasc       Date:  2021-09-15

7.  Symptom Severity and Health-Related Quality of Life in Patients with Atrial Fibrillation: Findings from the Observational ARENA Study.

Authors:  Monika Sadlonova; Jochen Senges; Jonas Nagel; Christopher Celano; Caroline Klasen-Max; Martin Borggrefe; Ibrahim Akin; Dierk Thomas; Christopher Jan Schwarzbach; Thomas Kleeman; Steffen Schneider; Matthias Hochadel; Tim Süselbeck; Harald Schwacke; Angelika Alonso; Markus Haass; Karl-Heinz Ladwig; Christoph Herrmann-Lingen
Journal:  J Clin Med       Date:  2022-02-21       Impact factor: 4.241

8.  Symptom Burden of Atrial Fibrillation and Its Relation to Interventions and Outcome in Europe.

Authors:  Renate B Schnabel; Ladislav Pecen; Nargiz Rzayeva; Markus Lucerna; Yanish Purmah; Francisco M Ojeda; Raffaele De Caterina; Paulus Kirchhof
Journal:  J Am Heart Assoc       Date:  2018-05-18       Impact factor: 5.501

9.  Excess short-term mortality in noncritical patients with atrial fibrillation presenting to the emergency department.

Authors:  Jan Niederdöckl; Michael Schwameis; Harald Herkner; Hans Domanovits
Journal:  Wien Klin Wochenschr       Date:  2021-06-21       Impact factor: 1.704

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.